GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (BOM:543064) » Definitions » EV-to-FCF

Suven Pharmaceuticals (BOM:543064) EV-to-FCF : (As of May. 30, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Suven Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Suven Pharmaceuticals's Enterprise Value is ₹160,570 Mil. Suven Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₹0 Mil. Therefore, Suven Pharmaceuticals's EV-to-FCF for today is .

The historical rank and industry rank for Suven Pharmaceuticals's EV-to-FCF or its related term are showing as below:

BOM:543064' s EV-to-FCF Range Over the Past 10 Years
Min: 0   Med: 0   Max: 112.15
Current: 94.92

During the past 5 years, the highest EV-to-FCF of Suven Pharmaceuticals was 112.15. The lowest was 0.00. And the median was 0.00.

BOM:543064's EV-to-FCF is ranked worse than
86.79% of 530 companies
in the Drug Manufacturers industry
Industry Median: 22.78 vs BOM:543064: 94.92

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-30), Suven Pharmaceuticals's stock price is ₹647.00. Suven Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹14.580. Therefore, Suven Pharmaceuticals's PE Ratio for today is 44.38.


Suven Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Suven Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Pharmaceuticals EV-to-FCF Chart

Suven Pharmaceuticals Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-FCF
- 8.91 46.25 60.05 70.36

Suven Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 70.36 - - -

Competitive Comparison of Suven Pharmaceuticals's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suven Pharmaceuticals's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Suven Pharmaceuticals's EV-to-FCF falls into.



Suven Pharmaceuticals EV-to-FCF Calculation

Suven Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=160569.557/0
=

Suven Pharmaceuticals's current Enterprise Value is ₹160,570 Mil.
Suven Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suven Pharmaceuticals  (BOM:543064) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Suven Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=647.00/14.580
=44.38

Suven Pharmaceuticals's share price for today is ₹647.00.
Suven Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹14.580.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Suven Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Suven Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Suven Pharmaceuticals (BOM:543064) Business Description

Traded in Other Exchanges
Address
3rd Floor, Road No. 5, Avenue 7, Banjara Hills, No. 8-2-334, SDE Serene Chambers, Hyderabad, TG, IND, 500034
Suven Pharmaceuticals Ltd is engaged in the development and manufacturing of Intermediates, Active Pharmaceutical Ingredients (API), specialty chemicals and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology and chemical companies. The company has single operating segment that is Pharmaceuticals Manufacturing & Services and its geographical segments include India; the USA; Europe and the Rest of the World. The company derives a majority of revenue from the Europe segment.

Suven Pharmaceuticals (BOM:543064) Headlines

No Headlines